A Proteomics Upstart Tries to Outrun the Competition

Science  07 Dec 2001:
Vol. 294, Issue 5549, pp. 2079-2080
DOI: 10.1126/science.294.5549.2079

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


GENEVA, SWITZERLAND-- By assembling an arsenal of technology--including a research lab here in the outskirts of Geneva, one under construction in New Jersey, and a possible one in Japan--GeneProt, the biggest test-bed to date in the young field of proteomics, aims to identify proteins associated with disease. The company is banking that these proteins will produce a string of lucrative drugs aimed at top killers such as cancer and heart disease. GeneProt's moves have inspired both awe and skepticism among other proteomics researchers.